Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematopoietic growth factors: Part II

T L Wandstrat1, M Wolfe

  • 1Robert C. Byrd Health Sciences Center, Charleston, WV 25304, USA.

Neonatal Network : NN
|October 1, 1996
PubMed
Summary

Anemia of prematurity (AOP) affects premature infants, often worsened by blood draws. Recombinant human erythropoietin (rh-EPO) effectively reduces transfusions, complementing other strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of HIV diagnosis disclosure on psychosocial outcomes in Thai children with perinatal HIV infection.

International journal of STD & AIDS·2015
Same author

Application of QSARs and VFARs to the rapid risk assessment process at US EPA.

SAR and QSAR in environmental research·2008
Same author

Inactivation of an invertebrate acetylcholinesterase by sulfhydryl reagents: a reconsideration of the implications for insecticide design.

Chemico-biological interactions·2008
Same author

Mixed modelling to characterize genotype-phenotype associations.

Statistics in medicine·2005
Same author

Collaborative partnership for optimizing heart failure outcomes in the long-term care environment: a clinical experience.

Journal of the American Medical Directors Association·2003
Same author

Treatment outcome among child psychiatric outpatients in a community mental health center.

Community mental health journal·2000

Area of Science:

  • Neonatal Medicine
  • Hematology
  • Pharmacology

Background:

  • Anemia of prematurity (AOP) is a common condition in premature infants.
  • Excessive phlebotomy in the NICU setting exacerbates AOP.
  • Erythrocyte transfusion was the primary therapy for AOP.

Purpose of the Study:

  • To evaluate the efficacy of recombinant human erythropoietin (rh-EPO) in treating AOP.
  • To assess rh-EPO as a prophylactic agent for AOP.
  • To determine if rh-EPO can reduce the need for erythrocyte transfusions in premature infants.

Main Methods:

  • Review of various studies utilizing rh-EPO for AOP treatment or prophylaxis.
  • Analysis of rh-EPO's role in conjunction with phlebotomy restriction and transfusion policies.

Main Results:

  • rh-EPO has demonstrated effectiveness in reducing erythrocyte transfusions for AOP.
  • rh-EPO serves as a complementary strategy to phlebotomy restriction and conservative transfusion policies.
  • These combined strategies decrease the number of transfusions required by premature infants.

Conclusions:

  • rh-EPO is an effective therapeutic and prophylactic option for AOP.
  • rh-EPO, combined with other measures, helps minimize transfusion needs in premature infants.
  • Further trials are needed to confirm cost-effectiveness and long-term effects of rh-EPO.

Related Experiment Videos